Aprinoia Therapeutics (Aprinoia Therapeutics) Cash, Cash Equivalents, Marketable Securities : $7.73 Mil (As of Jun. 2023)

View and export this data going back to 2050. Start your Free Trial

What is Aprinoia Therapeutics Cash, Cash Equivalents, Marketable Securities?

Aprinoia Therapeutics's quarterly cash, cash equivalents, marketable securities increased from Jun. 2022 ($0.00 Mil) to Dec. 2022 ($1.22 Mil) and increased from Dec. 2022 ($1.22 Mil) to Jun. 2023 ($7.73 Mil).

Aprinoia Therapeutics's annual cash, cash equivalents, marketable securities increased from . 20 ($0.00 Mil) to Dec. 2021 ($9.67 Mil) but then declined from Dec. 2021 ($9.67 Mil) to Dec. 2022 ($1.22 Mil).

Aprinoia Therapeutics Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Aprinoia Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aprinoia Therapeutics Cash, Cash Equivalents, Marketable Securities Chart

Aprinoia Therapeutics Annual Data

Trend

Dec21

Dec22

Cash, Cash Equivalents, Marketable Securities

9.67

1.22

Aprinoia Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
Cash, Cash Equivalents, Marketable Securities	9.67	-	1.22	7.73

Aprinoia Therapeutics Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Aprinoia Therapeutics (NAS:APRI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Aprinoia Therapeutics Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Aprinoia Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aprinoia Therapeutics (Aprinoia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aprinoia Therapeutics Inc (NAS:APRI) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Aprinoia Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in protecting patients' brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Neurodegenerative diseases are relentless and largely fatal, resulting from progressive loss of nerve cells in the brain and, depending on the specific disorders, can affect a broad range of cognitive, behavioral, and motor functions, such as memory, thinking, speaking, walking, and breathing. It is developing several different diagnostic and therapeutic platforms such as abnormal protein aggregates of tau and alpha synuclein ("?-Syn") that are toxic to brain cells.

Aprinoia Therapeutics (Aprinoia Therapeutics) Headlines

No Headlines